The post-semaglutide obesity-research wave - MariTide, CagriSema, amycretin, survodutide, petrelintide, orforglipron and the triple agonists. Amylin, dual glucagon agonism, GIP antagonism and the first oral non-peptide GLP-1, mechanism by mechanism, with the latest trial data. Investigational compounds, no marketing authorisation; research use only.
8 articles tagged “Next-Gen GLP-1”
Nearly every modern peptide program is, underneath, a half-life-engineering project - acylation, PEGylation, Fc fusion, once-weekly to once-monthly. A field map of that arms race, and the near-empty frontier it leaves behind: designing for rhythm, not duration. Research use only.
Obesity research has moved past GLP-1 alone. This hub maps the next-generation mechanisms - GIP agonism and antagonism, glucagon, and amylin - and the candidate landscape from tirzepatide and retatrutide to MariTide, CagriSema, survodutide, amycretin and petrelintide. Research use only.
Eli Lilly's once-daily oral small-molecule GLP-1 receptor agonist - not a peptide. Mechanism, the ATTAIN Phase 3 data (~12.4% at 72 weeks), why a pill changes access, and how it differs from the research peptides. Research use only.
Amgen's once-monthly peptide-antibody conjugate pairs GLP-1 agonism with GIP antagonism - the unusual mechanism, the Phase 2 data (up to ~20%), and where it sits in the obesity pipeline. Research use only.
Novo Nordisk's combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 agonist) - the mechanism, the REDEFINE Phase 3 data (~20-23%), and why amylin is the next obesity-research mechanism. Research use only.
Novo Nordisk's investigational single-molecule GLP-1 and amylin receptor agonist in oral and injectable development - the science, the early data (~22% injectable at 36 weeks), and how it compares to CagriSema. Research use only.
Boehringer Ingelheim's investigational GLP-1 / glucagon dual agonist studied for obesity and MASH - the mechanism, the SYNCHRONIZE program, the ~16.6% Phase 3 weight loss, and the distinctive liver-fat angle. Research use only.
Zealand Pharma and Roche's investigational long-acting amylin analogue - the amylin-first obesity strategy, the Phase 2 data (~10.7% at week 42), and why an amylin-only approach matters. Research use only.
Research use only. These articles summarise public literature and catalogue facts. They do not diagnose, treat, or prevent any disease, and are not medical advice.